Formerly AviaraDx Home | Contact | Sitemap
bioTheranostics
 
 

Theros H/ISM - Integration into Clinical Practice

Treatment options for breast cancer, including hormone therapy and/or chemotherapy, are chosen on the basis of endocrine responsiveness and prognostic risk factors.11 Comprehending a patient’s potential to benefit from endocrine therapy or chemotherapy is vital to understanding overall recurrence risk and best treatment options. Theros H/I goes beyond conventional tools for measuring estrogen and progesterone receptor status, and can better predict a patient’s likelihood to benefit or not benefit from endocrine therapy.

Research Collaborations

  • Harvard Medical School / MGH, Boston, MA
  • Mayo Clinic, Rochester, MN
  • Baylor College of Medicine, Houston, TX
  • Erasmus Medical Center, Netherlands
  • Linkoping University Hospital, Sweden

Sample and Technical Information

  • Robust real-time RT-PCR assay.
  • Requires one adjacent H&E and two unstained slides from formalin-fixed, paraffin embedded specimens.
  • Performed in a CAP accredited, CLIA-certified laboratory.
  • Results typically available within 3-5 working days of receipt of sample.

Link to publications

References:
1 Ma, et al. A Two-Gene Expression Ratio Predicts Clinical Outcome in Breast Cancer Patients Treated with Tamoxifen Cancer Cell 5:607-16, 2004.
2 Goetz, et al. A Two-Gene Expression of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen Clinical Cancer Research 12(7):2080-87, 2006.
3 Ma, et al. The HOXB13:IL17BR Expression Index is a Prognostic Factor in Early-Stage Breast Cancer. Journal of Clinical Oncology, 24(28):4611-19, 2006.
4 Jansen, et al. Retrospective Study of the HOXB13-to-IL17BR Expression Ratio Related to Tumor Aggressiveness and Response to Tamoxifen in Recurrent Breast Cancer. Journal of Clinical Oncology, 25(6):662-668, 2007.
5 Jerevall, et al. Exploring the Two-Gene Ratio in Breast Cancer–Independent Roles for HOXB13 and IL17BR in Prediction of Clinical Outcome. Breast Cancer Research Treatment 102, April 2007.
6 Wang, et al. The Prognostic Biomarkers HOXB13, IL17BR and CHDH Are Regulated by Estrogen in Breast Cancer. Clinical Cancer Research 13(21): 6327-6334, November 1, 2007.
7 Ma, et al. A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical Cancer Research 14(9): 2601-2608, May 1, 2008.
8 Fisher B, et al. Treatment of lymph-node negative, estrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet. 2004; 364: 858-868.
9 Miao, et al. HOXB13 Promotes Ovarian Cancer Progression. Proc Nat Acad Sci USA, 104:43, 17093-17098, 2006.
10 Sgroi, et al. Personal Communication, 2007.
11 Goldhirsch et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer. Ann Oncology 16: 1569-1583, 2005.

 | TOP |